首页 > 市场调查报告书 > 製药

癌症

市场调查报告书

商品编码

1741221

Dasatinib药物市场按类型、适应症、分销管道和地区划分

Dasatinib Drugs Market, By Type, By Indication, By Distribution Channel, By Geography

出版日期: 2025年03月26日 | 出版商:

Coherent Market Insights | 英文 160 Pages | 商品交期: 2-3个工作天内

价格

简介目录

Dasatinib药物市场规模预计在 2025 年达到 16.461 亿美元，预计到 2032 年将达到 24.751 亿美元，2025 年至 2032 年的复合年增长率为 6%。

报告范围		报告详细信息
基准年	2024	2025年的市场规模	16.461亿美元
效能数据	从2020年到2024年	预测期	2025年至2032年
预测期 2025-2032 年复合年增长率：	6.00%	2032年价值预测	24.751亿美元

Dasatinib是一种蛋白酪氨酸激酶抑制剂，彻底改变了某些癌症的治疗模式。Dasatinib尼最初被开发标靶治疗慢性骨髓性白血病(CML) 和费城染色体阳性急性淋巴细胞白血病 (Ph+ALL)，它特异性靶向并抑制 BCR-ABL 蛋白，从而抑制癌细胞的生长和增殖。由于其卓越的疗效，Dasatinib显着改善了这些恶性肿瘤患者的预后并提高了患者的存活率。此外，Dasatinib也显示出对其他蛋白酪氨酸激酶（包括 SRC 家族激酶）的抑制活性，从而拓宽了其在多种肿瘤中的潜在应用。儘管Dasatinib是一种很有前景的治疗选择，但它并非没有副作用，需要密切监测和管理。正在进行的研究和临床试验正在探索Dasatinib在联合治疗中的潜力，为癌症治疗策略的进一步发展铺平道路。

市场动态：

预计在预测期内，癌症发生率的上升、良好的临床疗效以及核准的扩大将推动全球Dasatinib药物市场的成长。此外，标靶治疗的市场发展也有望在预测期内推动全球Dasatinib药物市场的成长。新兴市场的发展、联合治疗、儿科适应症以及学名药的开发预计将为预测期内全球Dasatinib药物市场的成长提供成长机会。

然而，预计在预测期内，高昂的治疗成本、严格的监管要求、潜在的副作用以及抗药性的产生将阻碍Dasatinib药物市场的成长。

本研究的主要特点

本报告对全球Dasatinib药品市场进行了详细分析，并以 2024 年为基准年，展示了预测期 2025-2032 的市场规模和复合年增长率。
它还强调了各个领域的潜在商机，并说明了该市场的引人注目的投资提案矩阵。
它还提供了有关市场驱动因素、限制因素、机会、新产品发布和核准、市场趋势、区域前景和主要企业采用的竞争策略的主要考察。
它根据公司亮点、产品系列、关键亮点、业绩和策略等参数，介绍了全球Dasatinib药物市场的主要企业概况。
本报告的见解将使负责人和企业经营团队能够就未来的产品发布、高端市场策略、市场扩张和行销策略做出明智的决策。
全球Dasatinib药物市场报告迎合了该行业的各个相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
相关人员将透过用于分析全球Dasatinib药物市场的各种策略矩阵更轻鬆地做出决策。

Report Coverage	Report Details
Base Year:	2024	Market Size in 2025:	USD 1,646.1 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2025 To 2032
Forecast Period 2025 to 2032 CAGR:	6.00%	2032 Value Projection:	USD 2,475.1 Mn

Dasatinib is a potential tyrosine kinase inhibitor that has revolutionized the treatment landscape for certain types of cancer. Initially developed as a targeted therapy for chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL), dasatinib specifically targets and inhibits the BCR-ABL protein, suppressing the growth and proliferation of cancer cells. With remarkable efficacy, dasatinib has significantly improved outcomes and increased survival rates in patients with these malignancies. Moreover, dasatinib exhibits inhibitory effects on other tyrosine kinases, including SRC family kinases, broadening its potential application to various tumors. While dasatinib offers a promising therapeutic option, it is not without side effects, necessitating careful monitoring and management. Ongoing research and clinical trials are exploring the potential of dasatinib in combination therapies, paving the way for further advancements in cancer treatment strategies.

Market Dynamics:

The increasing prevalence of cancer, favorable clinical outcomes, and expansion of approved indications are anticipated to drive the growth of the global dasatinib drugs market over the forecast period. Moreover, the development of targeted therapies is also expected to boost the growth of the global dasatinib drugs market over the forecast period. Expansion into emerging markets, combination therapies, pediatric indications, and the development of generic versions are expected to create growth opportunities for the global dasatinib drugs market growth during the forecast period.

However, the high cost of treatment, stringent regulatory requirements, potential adverse effects, the development of resistance are expected to hamper the growth of the dasatinib drugs market over the forecast period.

Key features of the study:

This report provides an in-depth analysis of the global dasatinib drugs market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global dasatinib drugs market based on the following parameters - company highlights, product portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Bristol-Myers Squibb Company, MSN Labs, Lupin, Dr. Reddy's Laboratories, Gilead Sciences, Inc., Hetero Labs, MANUS AKTTEVA BIOPHARMA LLP, Alembic Pharma, JINLAN Pharm-Drugs Technology Co., Ltd., and Zhejiang Hisun Pharma
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global dasatinib drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global dasatinib drugs market

Detailed Segmentation:

Dasatinib Drugs Market, By Type:
- 20 mg
- 50 mg
- 70 mg
Dasatinib Drugs Market, By Indication:
- Chronic Myeloid Leukemia
- Acute Lymphoblastic Leukemia
- Others
Dasatinib Drugs Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Dasatinib drugs market, By Region:
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East
- Africa
Company Profiles:
- Bristol-Myers Squibb
- MSN Labs
- Lupin
- Dr. Reddy's Laboratories
- Hetero Labs
- MANUS AKTTEVA BIOPHARMA LLP
- Alembic Pharma
- JINLAN Pharm-Drugs Technology Co., Ltd.
- Reddy's Laboratories
- Zhejiang Hisun Pharma

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Type
- Market Snippet, By Indication
- Market Snippet, By Distribution channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
Increasing prevalence of cancer
- Restraints
Increasing product recall
- Opportunities
Expansion into emerging markets
Combination therapies
Pediatric indications
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Dasatinib Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

COVID-19 Epidemiology
Supply Side and Demand Side Analysis
Economic Impact

5. Dasatinib Drugs Market, By Type, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
20 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
50 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
70 mg
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

6. Dasatinib Drugs Market, By Indication, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Chronic Myeloid Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Acute Lymphoblastic Leukemia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

7. Dasatinib Drugs Market, By Distribution Channel, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Mn)

8. Dasatinib Drugs Market, By Region, 2020-2032, (US$ Mn)

Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.S.
  - Canada
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - China
  - India
  - Japan
  - Australia
  - South Korea
  - ASEAN
  - Rest of Asia Pacific
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Mn)
  - GCC Countries
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Type, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Indication, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2020-2032, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Mn)
  - North Africa
  - South Africa
  - Central Africa

9. Competitive Landscape

Bristol-Myers Squibb
- Company Highlights
Product Portfolio
Key Developments
Financial Performance
Strategies
- MSN Labs
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Hetero Labs
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Alembic Pharma,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- JINLAN Pharm-Drugs Technology Co., Ltd.,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Reddy's,
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Zhejiang Hisun Pharma
Company Highlights
Product Portfolio
Key Highlights
Financial Performance
Strategies
- Analyst Views

10. Section

Research Methodology
About us

02-2729-4219

+886-2-2729-4219

License/价格

Dasatinib药物市场按类型、适应症、分销管道和地区划分